A Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-42160443 in Subjects With Postherpetic Neuralgia and Post-traumatic Neuralgia, Followed by a Double Blind Safety Extension and an Open-label Safety Extension.

Trial Profile

A Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-42160443 in Subjects With Postherpetic Neuralgia and Post-traumatic Neuralgia, Followed by a Double Blind Safety Extension and an Open-label Safety Extension.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 26 Aug 2014

At a glance

  • Drugs Fulranumab (Primary)
  • Indications Neuropathic pain
  • Focus Therapeutic Use
  • Sponsors Janssen-Cilag
  • Most Recent Events

    • 31 Aug 2012 Results presented at the 14th World Congress on Pain.
    • 27 Aug 2012 Primary endpoint 'Pain-intensity' (assessed on a numerical rating scale) has not been met (based on information presented at 14th World Congress on Pain); however, only 111 of the planned 200 patients were enrolled.
    • 30 Mar 2012 Actual patient number is 112 according to ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top